Celcuity Inc. (NASDAQ:CELC) is one of the best high short interest stocks with highest upside potential. On May 14, Celcuity ...
Women who’ve been treated for hormone-sensitive breast cancer often face five to 10 years of endocrine therapy to lower the chances of their tumors coming back. Because that drug regimen is toxic ...
A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...
More information on these findings will be presented at the 2026 ASCO Annual Meeting on June 1. The data come from a new ...
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more ...
Morning Overview on MSN
A new genomic test could spare two-thirds of high-risk breast cancer patients from chemotherapy entirely, per ASCO 2026 results
Thousands of women diagnosed with high-risk, estrogen-receptor-positive breast cancer may no longer need chemotherapy, ...
Nancy E. Davidson, MD, executive vice president and chief academic officer at Fred Hutch Cancer Center, is the recipient of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results